TCRX Stock Overview
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
TScan Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.69 |
52 Week High | US$9.00 |
52 Week Low | US$1.62 |
Beta | 0.90 |
1 Month Change | 8.01% |
3 Month Change | 32.36% |
1 Year Change | 280.69% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -26.76% |
Recent News & Updates
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17Recent updates
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18Shareholder Returns
TCRX | US Biotechs | US Market | |
---|---|---|---|
7D | 4.8% | -2.8% | -1.7% |
1Y | 280.7% | -0.2% | 22.4% |
Return vs Industry: TCRX exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: TCRX exceeded the US Market which returned 22.4% over the past year.
Price Volatility
TCRX volatility | |
---|---|
TCRX Average Weekly Movement | 10.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TCRX's share price has been volatile over the past 3 months.
Volatility Over Time: TCRX's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 154 | Gavin MacBeath | www.tscan.com |
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors.
TScan Therapeutics, Inc. Fundamentals Summary
TCRX fundamental statistics | |
---|---|
Market cap | US$371.09m |
Earnings (TTM) | -US$89.22m |
Revenue (TTM) | US$21.05m |
17.5x
P/S Ratio-4.1x
P/E RatioIs TCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TCRX income statement (TTM) | |
---|---|
Revenue | US$21.05m |
Cost of Revenue | US$88.15m |
Gross Profit | -US$67.10m |
Other Expenses | US$22.11m |
Earnings | -US$89.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.86 |
Gross Margin | -318.80% |
Net Profit Margin | -423.86% |
Debt/Equity Ratio | 19.9% |
How did TCRX perform over the long term?
See historical performance and comparison